|Traded as||NASDAQ: TTNP|
Number of employees
|13 (June 2015)|
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”) for the treatment of opioid addiction or chronic pain. Template:As of 2015, it was in phase 3 trials.
- Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
- "Probuphine® Program Update". Titan Pharmaceuticals. Retrieved 21 September 2015.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|